ZYLOX-TONBRDG.MED.TECH.H1 Total Assets
ZYLOX-TONBRDG.MED.TECH.H1 total assets. Based on the latest financial reports, ZYLOX-TONBRDG.MED.TECH.H1 (818) holds total assets worth €3.50 Billion EUR (≈ $4.09 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is ZYLOX-TONBRDG.MED.TECH.H1 worth for the company's overall valuation and market capitalisation.
Total Assets of ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
Total assets of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024. This chart illustrates how ZYLOX-TONBRDG.MED.TECH.H1's total assets have evolved over time, based on quarterly financial data. See ZYLOX-TONBRDG.MED.TECH.H1 (818) stock price for real-time trading data and today's change.
ZYLOX-TONBRDG.MED.TECH.H1 - Asset Composition Analysis
ZYLOX-TONBRDG.MED.TECH.H1 Total Assets Breakdown (December 2024)
ZYLOX-TONBRDG.MED.TECH.H1 total assets breakdown as of December 2024. ZYLOX-TONBRDG.MED.TECH.H1's total assets of €3.50 Billion consist of 44.3% current assets and 55.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.1% |
| Accounts Receivable | €1.54 Million | 0.0% |
| Inventory | €205.48 Million | 6.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €61.38 Million | 1.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how ZYLOX-TONBRDG.MED.TECH.H1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is ZYLOX-TONBRDG.MED.TECH.H1's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ZYLOX-TONBRDG.MED.TECH.H1's current assets represent 44.3% of total assets in 2024, a decrease from 93.1% in 2021.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, down from 43.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 6.0% of total assets.
ZYLOX-TONBRDG.MED.TECH.H1 Competitors by Total Assets
Key competitors of ZYLOX-TONBRDG.MED.TECH.H1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥916.43 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.57 Billion |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
Pulsenmore Ltd
TA:PULS
|
Israel | ILA120.34 Million |
|
Adherium Ltd
AU:ADR
|
Australia | AU$4.16 Million |
ZYLOX-TONBRDG.MED.TECH.H1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.77 | 3.85 | 3.85 |
| Quick Ratio | 5.16 | 3.38 | 3.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.54 Billion | €1.02 Billion | €1.02 Billion |
ZYLOX-TONBRDG.MED.TECH.H1 - Advanced Valuation Insights
This section examines the relationship between ZYLOX-TONBRDG.MED.TECH.H1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.73 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 2.3% |
| Total Assets | €3.45 Billion |
| Market Capitalization | $708.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values ZYLOX-TONBRDG.MED.TECH.H1's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ZYLOX-TONBRDG.MED.TECH.H1's assets grew by 2.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below shows the annual total assets of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €3.45 Billion ≈ $4.04 Billion |
+2.28% |
| 2023-12-31 | €3.38 Billion ≈ $3.95 Billion |
+3.75% |
| 2022-12-31 | €3.25 Billion ≈ $3.80 Billion |
+0.17% |
| 2021-12-31 | €3.25 Billion ≈ $3.80 Billion |
-- |
About ZYLOX-TONBRDG.MED.TECH.H1
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracrania… Read more